Kromann Advises Roche On $450M Santaris Buy
Swiss pharmaceutical giant Roche Holding AG will purchase Copenhagen-based biotech company Santaris Pharma A/S Corp. for up to $450 million in an effort to develop RNA-targeting therapies for difficult-to-treat diseases, according...To view the full article, register now.
Already a subscriber? Click here to view full article